Seattle Genetics and Oxford BioTherapeutics (OBT) have formed a collaboration to discovery novel antibody-drug conjugates against cancer. OBT will create panels of mAbs against tumor-specific antigens identified using its Oxford Genome Anatomy Project (OGAP®) database. These will be screened using Seattle’s ADC technology.
The OGAP database is built on disease protein information generated by OBT in-house coupled with genetic and clinical data from 50 different human tissues, including 5,000 cancer membrane proteins. OBT claims the database integrates all clinical and experimental expression data from about 1 million human protein peptide sequences, 15000 validated genes, 50 tissues/organs, 58 diseases, and about 8 million SNPs and haplotypes.
Under the deal's terms, the firms will have an equal number of alternating options to select programs from preclinical ADCs for exclusive, worldwide development and commercialization. Each firm will receive progress-dependent milestone payments and royalties on net sales of any resulting ADCs developed by its partner.
Seattle Genetics is focused on the development of antibody-based therapeutics against cancer. Its ADC drug Adcetris was recently FDA approved for two indications: Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL). Seattle Genetics has three additional ADC candidates undergoing Phase I testing: SGN-75 is in development against renal cell carcinoma and non-Hodgkin lymphoma, ASG-5ME is being evaluated for the treatment of pancreatic cancer and prostate cancer, and ASG-22ME is in development against solid tumors. See GEN.
Posted by Bruce Lehr Sep 18th 2011.